TD Asset Management’s BridgeBio Oncology BBOT Stock Holding History

TD Asset Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Sell	42,730 -14,842	-26%	-$124K	﹤0.01%	1199
2026 Q1	$515K	Sell	57,572 -59,578	-51%	-$640K	﹤0.01%	1170
2025 Q4	$1.47M	Sell	117,150 -12,912	-10%	-$156K	﹤0.01%	1041
2025 Q3	$1.51M	Sell	130,062 -14,710	-10%	-$153K	﹤0.01%	1021
2025 Q2	$1.54M	Hold	144,772	–	–	﹤0.01%	994
2025 Q1	$1.64M	Hold	144,772	–	–	﹤0.01%	1010
2024 Q4	$1.52M	Hold	144,772	–	–	﹤0.01%	1063
2024 Q3	$1.51M	Hold	144,772	–	–	﹤0.01%	1114
2024 Q2	$1.48M	Buy	+144,772	New	+$1.49M	﹤0.01%	1079

Other funds holding BBOT

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TD Asset Management's BBOT Position: Q2 2026 in Review

TD Asset Management reduced its BridgeBio Oncology (BBOT) stake by 26% in Q2 2026, selling an estimated $124K and leaving 42,730 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1199.

TD Asset Management first reported a position in BBOT in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.64M in Q1 2025. 29 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

TD Asset Management held 42,730 shares of BridgeBio Oncology worth $326K as of Q2 2026.
TD Asset Management sold 14,842 BridgeBio Oncology shares in Q2 2026, an estimated $124K.
BridgeBio Oncology made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1199 holding.
TD Asset Management first reported a position in BridgeBio Oncology in Q2 2024 and has held it in 9 quarters since.
TD Asset Management's BridgeBio Oncology position peaked at $1.64M in Q1 2025.
29 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.